ArticleInternational journal of radiation oncology, biology, physics2026
Pace of Cervical Cancer Stage Progression Prior to Radiation Therapy Initiation, an Instrumental Variable Analysis.
Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeIn initiating radiation therapy for cervical cancer are common and may contribute to poorer outcomes. However, the pace of stage progression remains uncertain, limiting the development of quality targets and mitigation strategies. Delays in initiating radiation therapy for cervical cancer are common and contribute to poorer outcomes. We sought to estimate the pace of stage progression to guide development of quality targets and mitigation strategies. METHODS AND MATERIALS: We conducted a prospective cohort study of women with cervical cancer treated with radiation in Botswana between 2012 and 2019. We used an instrumental variable approach based on seasonal variation in access to treatment to estimate the causal effect of treatment delay on cancer stage progression. The month of cancer diagnosis served as a natural source of variation, with women diagnosed during end-of-year holiday disruptions (November-February) experiencing longer delays on average than women at other times of the year. Using two-stage weighted models of mean delay and mean cancer stage at time of treatment, we estimated the average time required for cervical cancer stage to progress (eg, IIIA and IIIB). To contextualize findings we examined the association between cancer stage at treatment initiation and overall survival.
resultsAmong 763 eligible participants, 494 were diagnosed during routine access periods and 269 during delayed periods. The mean time to treatment initiation was longer (instrumental variable partial F-statistic 13.1) in the delayed-access group (12.4 weeks) compared with the routine access group (11.2 wk). The groups were otherwise well-balanced. In the primary analysis, cervical cancer stage progression was estimated to occur over a mean of 8.6 weeks (95% CI, 7.1-10.9). Modeled time to stage progression differed by HIV status (P < .001), with estimated 7.6 weeks (95% CI, 6.4-9.2) for women with HIV and 8.7 weeks (95% CI, 6.1-15.3) for women without HIV. Stage increase was associated with a 38% reduction in survival time (95% CI, 33%-44%).
conclusionsModest treatment delays commonly encountered in routine care were associated with measurable cervical cancer progression, likely decreasing survival. Initiating treatment within 4 weeks from diagnosis minimizes the risk of stage progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.